Updated April 11, 2013
Chimerix raises more than $100 million. The RTP firm plans to use IPO proceeds to fund R&D, particularly phase III clinical trials on its lead therapeutic program.
Chimerix drug pipeline as cited in IPO filing.
Updated April 11, 2013
Talecris Biotherapeutics, once one of the largest life science firms in the Triangle, is no more since its assets were incorporated into Spain-based Grifols as part of a $4 billion merger. But the investment Grifols made in acquiring Talecris two years ago, continues to pay dividends.
Updated April 24, 2012
The Spain-based blood plasma firm reports big jump in sales and profits in wake of RTP-based Talecris takeover.
February 1, 2012
The Spain-based maker of blood plasma products is seeking to refinance the debt it raised in order to buy its rival Talecris, according to Bloomberg news.
June 8, 2011
Spain-based Grifols, the new owner of RTP-based Talecris Biotherapeutics, said Wednesday that the company plans to proceed with expansion of the massive Talecris expansion plant in nearby Clayton.
Updated June 6, 2011
The Spain-based life sciences company, which acquired RTP-based Talecris for more than $3 billion, puts in place a former Baxter executive and a team to oversee integration of the two companies.
Updated June 1, 2011
The closing could take place as early as Wednesday now that the FTC has formally signed off on the deal, the RTP-based biotherapeutics firm says.
May 24, 2011
At a shareholders meeting in Spain on Tuesday, Grifols said in a statement that it expects final regulatory approval for the $4 billion deal in early June, according to Reuters.
April 28, 2011
The RTP-based biotherapeutics firm is still awaiting approval of its proposed merger with Spain-based Grifols.
April 11, 2011
"There is a high level of confidence that they're going to get approval any day," a vice president of merger arbitrage trading and sales at Wall Street Access tells Bloomberg news. "I'm still taken aback as to why this has taken so long."
April 7, 2011
The Spain-based life sciences firm is awaiting FTC decision on $3.8 billion deal for Triangle-based blood plasma therapeutics producer.
March 4, 2011
The companies are still seeking US government approval for the deal that would combine two of the world's largest plasma-based therapeutics providers.
February 24, 2011
The biotherapeutics firm reports a 38-cent per share quarterly profit and says its revenues increased 4.5 percent for the year to $1.6 billion.
February 11, 2011
As FTC decision looms, the Spanish life sciences firm pushes back the possible closing of the $4 billion deal to take over RTP-based Talecris.
February 4, 2011
Reuters news reports that the Spanish company apparently is still talking to US regulators about the buyout of the RTP-based biotherapeutics firm.
January 17, 2011
Shareholders will be asked to approve the multi-billion deal on Feb. 14.
January 13, 2011
The Spain-based life sciences conglomerate is in the process of acquiring RTP-based Talecris Biotherapeutics. It had hoped to sell the bonds in December.
December 14, 2010
The RTP-based plasma therapeutics firm and Plasma Centers of America were fighting over a terminated acquisition agreement.
December 1, 2010
The Spanish pharmaceutical firm said last week that it had the money lined up for the $3.4 billion deal.
November 25, 2010
The RTP-based blood plasma therapeutics firm would become part of the Spanish conglomerate if regulators approve the merger.